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Abstract 
Background:  Alcohol use disorder (AUD) is a significant health problem in the U.S.  Specifically, AUD 
is associated with memory problems and other cognitive defects.  DNA methylation of CpG sites and 
other epigenetic factors have been found to play an important role in the development of Alcohol Use 
Disorders (AUD).  Because of this, it was hypothesized that individuals with AUD would show 
differential methylation in neurotrophic factors, specifically, the BDNF gene, as compared to controls.  
Methods:  Precuneus brain tissue from 49 Alcohol Use Disorder cases and 47 controls were obtained 
from the New South Wales and Victorian Tissue Resource Centre.   DNA from each sample was 
extracted, and methylation levels were analyzed using Infinium HumanMethylation450 BeadChip.  
450,000 CpG sites were interrogated between AUD cases and controls; however, only 97 CpG sites in the 
Brain-derived neurotrophic factor (BDNF) gene were analyzed. 
Results:  Of the 97 CpG sites in the BDNF gene, only 4 displayed significant methylation differences 
between AUD cases and controls with the employment of a Bonferroni p-value correction.  To obtain 
more accurate results of overall methylation, CpG sites were grouped according to gene loci (Promoter, 
5’UTR, first exon, gene body, and 3’UTR).  Only the gene body of the BDNF gene approached 
significance (p=0.093) for a difference in methylation between AUD cases and controls with AUD cases 
being slightly hypomethylated. 
Conclusion:  No BDNF gene regions were found to be differentially methylated in the AUD group.  This 
could be due to the small and homogenous sample. However, one CpG region in the gene body 
approached statistical significance. Overall, gene body methylation is important for splicing kinetics.  
This may lead to different BDNF mRNA transcripts being produced between AUD cases and controls 
which can affect the half-life of BDNF mRNA. Future research is needed to examine this possibility in a 
larger study. 
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 Introduction 
 Alcohol use disorder (AUD) affects over 17 million adults over the age of 18 in the 
United States.  It can also extend to adolescents in which 855,000 individuals aged 12-17 were 
affected by the disorder in 2012 (National Institute of Alcohol Abuse and Alcoholism, 2012).  
Alcohol is known to affect the function of several organs including the brain and nervous system 
which ultimately leads to cognitive dysfunction.  Short-term alcohol use can cause slurred 
speech, breathing difficulties, impaired judgment, and memory lapses.  However, long-term 
alcohol use can cause permanent brain damage that results in impairment of executive functions 
and working memory (Finn et al., 1999). AUD is currently diagnosed through specific criteria 
issued by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
which looks at drinking habits and the effects of alcohol on social interactions.  It should be 
noted that in the new edition of the DSM, an additional criterion for alcohol craving was added.  
With this, fMRI data also show differential activation of the thalamus, precuneus, and middle 
temporal gyrus between AUD and non-AUD phenotypes when presented with alcohol related 
stimuli (Schacht et al., 2013).  This suggests activations in areas such as the precuneus are 
important in the manifestation of AUD. 
Pathologically, AUD is complex but can manifest through several factors such as 
socioeconomic status, peer influence, and social perceptions.  More recent research suggests an 
added epigenetic factor (Weng et al., 2014).  Epigenetics as a whole can be described as the 
alteration in gene expression while the sequence of DNA bases remains unchanged.  This 
alteration in gene expression is often associated with a change in chromatin structure or DNA-
protein interactions via chemical modifications.  These chemical modifications often include but 
are not limited to acetylation, ubiquitination, and phosphorylation of histone proteins that aid in 
condensing DNA. In particular, this study looks at direct methylation of cytosine residues on 
CpG islands.  The term CpG comes from an upstream cytosine residue adjacent to a guanosine 
residue in a given DNA sequence.  The cytosine residue of this specific dinucleotide sequence 
can be methylated by DNA methyl-transferase to 5-methylcytosine.  This chemical modification 
has been found to alter transcription factor association to DNA and can limit access of 
transcription factors to gene regulatory regions thus altering downstream gene expression.  
Promoter regions and other regulatory elements are especially important to observe methylation 
patterns as they are directly associated with transcriptional machinery (Deaton, Bird 2011).  
Therefore, a change in methylation pattern in one of these regions may significantly alter gene 
expression.  
It is important to note that epigenetics is largely based on environmental cues.  It allows 
the genome to turn on or off certain genes in order to adapt to current surroundings and needs.  
Thus, research shows that chronic alcohol consumption can induce differential methylation in 
AUD vs. non-AUD phenotypes (Choi et al., 1999).  Furthermore, heavy alcohol consumption 
and general alcohol use disorders are associated with an increase in genomic methylation 
(hypermethylation) particularly in a gene promoter area and other regulatory regions (Bönsch et 
al. 2006).  One study looked at 384 CpG sites in promoter regions of 82 candidate genes and 
found that there was a significant hypermethylation between the AUD cases and controls (Zhang 
et al., 2013).  Other studies have demonstrated that hypermethylation of a promoter region leads 
to a decrease in gene expression (Ouku et al., 2009).  This evidence seems to point towards a 
decrease in gene expression for AUD cases.  Interestingly, gene expression levels of 
neurotrophic factors have been found to be lower in AUD cases vs controls (Han et al., 2015). 
As a whole, neurotrophic factors aid in the survival of developing neurons and maintain 
mature neurons.  In particular, brain-derived neurotrophic factor (BDNF) inflect dendritic 
complexity and spine density.  Therefore, levels of BDNF can correlate to neuroadaptability and 
cognitive functioning.  From a mechanistic standpoint, BDNF is released from postsynaptic 
vesicle and binds to tyrosine kinase receptors (Trk) on the postsynaptic membrane during 
neuronal depolarization.  This causes an auto-phosphorylation of the Trk which in turn activates 
the MAP kinase pathway to alter the gene expression of the targeted neuron (Yoshii et al., 2010).  
These changes in gene expression are primarily implicated in the proliferation of new neurons 
and creation of new synaptic connections.  Auto-phosphorylation of the Trk receptor via BDNF 
also activates CaMKII, a kinase involved in long-term potentiation which strengthens neuronal 
pathways (Yoshii et al., 2010).   With this in mind, BDNF expression is implicated in 
neurological diseases, disorders, as well as cognitive disorders.  For example, previous research 
has been done to show that changes in activities and levels of BDNF are associated with 
cognitive dysfunctions such as memory formation and storage (Mattson 2004).  Because AUD is 
associated with some degree of cognitive defects, the role of BDNF in AUD was explored deeper 
at an epigenetic level.  This was done to analyze one aspect of the environmental effects on the 
pathogenesis of AUD. 
Overall, the aim of this study is to observe the methylation pattern of the BDNF gene in 
AUD cases vs. non-AUD controls.  It is hypothesized that because AUD is associated with 
cognitive dysfunction that the BDNF gene will be differentially methylated when compared to 
controls.  This is ultimately because BDNF is associated with cognitive function and 
neuroadaptability.  Differences in the cognitive function of AUD could be explained, but may 
not be limited to a differential methylation of the BDNF gene. It is important to note that 
aberrant methylation patterns are cell specific.  It is imperative that areas of the brain which are 
affected by a certain disorder be studied directly.  This puts a constraint on the current study in 
that brain tissue can only be collected post-mortem. 
Methods and Materials  
Samples 
Samples of frozen precuneus brain tissue samples from the 49 cases that met a DSM-IV 
diagnosis of alcohol dependence and 47 controls were obtained from the New South Wales and 
Victorian Tissue Resource Centre. The precuneus was specifically targeted because fMRI 
analysis shows differential activation between AUD cases and controls in regions such as the 
precuneus during presentation of alcohol-related cues (Schacht et al., 2013). Each AUD case was 
matched to a control based on age, post mortem interval (PMI), and gender (table 1).  It should 
be noted that of the tissue samples, 97.9 % of the AUD and 87.2% of the control group were 
Caucasian.  Alcohol dependence was confirmed by review of hospital medical records, physician 
interviews, and questionnaires to next-of-kin.  Reports of alcohol dependence from pathology, 
radiology and neuropsychology were also taken into account. Cause of death was determined by 
medical records and given to us along with the samples by the New South Wales and Victorian 
Tissue Resource Centre (table 2). 
DNA Isolation and methylation analysis  
Precuneus samples were stored initially at -800C.  Precuneus tissue was treated with 
Qiagen®’s Puregene DNA prep kits in order to isolate DNA (Qiagen®, Venlo, Limburg).  DNA 
yields were determined via PicoGreen® and fluorimetry (Qubit®, Life Technologies). The 
Illumina® Infinium® Assay Platform along with the Infinium HumanMethylation450 BeadChip 
was used for whole genome methylation interrogation. The array interrogates 480,000 CpG sites 
which covers 99% of Reference Sequence genes. The array covers the promoter, 5'UTR, first 
exon, gene body, and 3'UTRof each gene.  Zymo EZ DNA Methylation Kit was used to treat 600 
ng of genomic DNA with sodium bisulfite.  Sodium bisulfite converts unmethylated cytosines to 
uracil while methylated cytosines are not converted. The DNA was then purified and quantified 
by measuring absorbance at 260 nm in preparation for whole genome amplification.  The 
purified DNA was then fragmented and precipitated using ethanol. Hybridization buffer was 
used to resuspend the DNA, which was then applied to the bead chip array.  The chip was 
allowed to incubate overnight. Finally, the arrays were then washed to eliminate un-hybridized 
and non-specifically hybridized DNA. Next, the samples underwent single base extension and 
staining followed by more washing. The arrays were allowed to dry and then scanned using the 
Illumina iScan system.  
 Methylation was analyzed via two probe types. Type I probes incorporated florescent 
labels for detection at allele-specific single base extensions. Type II probes employed green dye 
colors to detect methylated (M) and red dye colors to detect unmethylated (U) signals using one 
probe per CpG locus. Illumina’s GenomeStudio software was used to quantify methylation 
signals and annotate each site (e.g. transcription start site proximity, gene name, and presence of 
a single nucleotide polymorphism (SNP)). Summaries of the probe interrogations yield average 
signals for methylated (M) and unmethylated (U) alleles at each CpG site, which are used to 
compute a -value, or ratio of overall methylation: 
 = Max(M,0)/(M+U+100) 
For example, a -value of 0 would indicate an unmethylated CpG site while a -value of 
1 indicates a fully methylated site. The -values of AUD cases and controls were then analyzed 
using SPSS statistics and univariate ANCOVA tests to co-vary out for age relate methylation 
changes. 
Results 
 The Infinium HumanMethylation450 BeadChip contained 97 CpG sites in the BDNF 
gene.  With 95% confidence, 4 out of the 97 CpG sites in the BDNF gene were found to display 
a statistical difference in methylation with a Bonferroni correction (table 3).  CpG sites that 
approached significance (0.05 < p < 0.1) were also reported. 
 Methylation sites that are spread out over the gene do not seem to hold much statistical 
significance, so each CpG was grouped based on gene loci in the BDNF gene.  These locations 
included CpG sites in the promoter, 5’UTR, first exon, gene body, and 3’UTR.  -values of each 
group were averaged to provide the overall methylation of a given gene location (table 4).  The 
methylation of these gene locations were then compared via ANCOVA analysis with a 
Bonferroni p-value correction.  Results show that when averaged by location, there was not a 
significant difference in methylation between AUD cases and controls, however, the gene body 
approached significance and displayed hypomethylation for AUD cases (Figures 1-5).  
 
Discussion 
 Overall, the analysis does not provide evidence of a significant change in methylation 
between the AUD cases and controls.  This could be due to the limited sample size (n=97) which 
was primarily comprised of Caucasian brains.  If the sample size were increased and taken from 
a more diverse population, perhaps it would be possible to see methylation differences indicative 
of a true population. 
 It is important to note that the change in methylation between AUD cases and controls 
approached significance in the gene body (p=0.093).  If the study was extended, perhaps a 
significant value could be obtained for the difference in methylation between the AUD cases and 
controls.  Due to this, it is important to speculate and discuss a significant gene body methylation 
pattern. 
 Methylation of CpG sites in the gene body has been shown to have important applications 
for mRNA splicing (Jones 2012).  During transcription, RNA polymerase reads the template 
stand of DNA in order to build an RNA transcript.  When RNA polymerase encounters a 
methylated CpG, the rate of transcription slows.  This allows for spliceosomes to interact with 
the nascent RNA strand for a slightly extended period of time which may result in alternative 
splicing.  Furthermore, alternative splicing produces different transcripts which may affect the 
stability of the mRNA or BDNF protein.  Because of this, BDNF could be produced at different 
levels between AUD cases and controls depending on if splicing effects the cytosolic stability of 
the mRNA.  Due to this, if splicing difference between AUD cases vs controls exist, then it 
would be important to sequence mRNA or to create a cDNA library for AUD cases vs controls.  
This could be used to compare mRNA transcript differences of not only BDNF, but other genes 
that may be differentially activated and spliced between the two conditions. 
 Furthermore, future research should analyze methylation of the BDNF gene in other areas 
of the brain.  For example, AUD is associated with cognitive and memory defects.  This points 
towards functional differences in the hippocampus and temporal lobes.  Since methylation is 
tissue specific, these areas may exhibit different methylation patterns than those shown in the 
precuneus (Davies et al., 2012).  This would provide a greater insight as to if BDNF is 
differentially methylated throughout the brain and its implication in AUD. 
 Another aspect of the study that was not commented on was the presence of single 
nucleotide polymorphisms (SNPs) within the BDNF gene of AUD cases and controls.  It is 
possible that a SNP could position a cytosine upstream from a guanosine or a guanosine 
downstream from a cytosine to create a CpG site.  The reverse is also possible in that a SNP 
could change a cytosine or guanosine to eliminate a CpG site.  This would create or destroy a 
CpG site that is not seen other AUD cases and controls to provide a slightly different methylation 
pattern which may influence gene expression.  Because these SNPs may be present in AUD 
cases and controls, future research should examine these locations to see if they are also 
differentially methylated or to see if AUD cases tend to have common SNPs when compared to 
controls. 
 As a whole, the analysis of the BDNF gene in AUD cases vs controls provides some 
insight in to the epigenetic and environmental effects of alcohol use disorder.  Overall, the nature 
of studying post-mortem brains limits available information.  In the case of this study, the 
diagnosis of AUD had to be determined through a series of interviews and questionnaires.  
Although these sources are assumed to be credible, it is not a first-hand account of drinking 
habits.  Finally, because brain tissue can only be collected post-mortem perhaps further research 
can establish a non-invasive procedure that correlates to the methylation patterns found in the 
brain.  This would provide a more holistic approach towards CpG methylation epigenetics that 
can be studied in a living organism as its environment changes. 
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TABLES 
Table 1:  Age and sex breakdown of post –mortem AUD brains (n=49) and controls (n=47).  
Post mortem index refers to the time between death and tissue collection (hours). 
 AUD Case (n=49) Controls (n=47) P 
AGE Mean: 47.76  
Standard Deviation: 7.78 
Mean: 48.43 
Standard Deviation: 8.38 
.6859 
SEX Female: n = 11 
Male: n = 38 
Female: n = 12 
Male: n=35 
0.9088 
POST MORTEM 
INDEX 
Mean: 35.58 
Standard Deviation: 
13.98 
Mean: 28.78  
Standard Deviation: 12.09 
0.032 
Table 2: Cause of Death breakdown for AUD cases (n=49) and controls (n=47) 
 Cardiac Respiratory Toxicity Vascular  Hepatic Neurological Trauma Obesity Blood 
Loss 
Other 
Controls 37 4 1 1 0 0 0 0 0 3 
AUD 
Cases 
14 9 12 0 5 1 1 1 3 3 
Table 3: Average methylation value of significant (p<0.05) and approaching significant 
(0.05<p<0.1) CpG sites in the BDNF gene. Reported numbers are averaged β-values.  P values 
reported after Bonferroni correction. 
CpG Site Methylation 
AUD Cases 
(Average β-
value) 
Methylation 
Controls 
(Average β-
value) 
P-Value 
Cg02723558       Mean 
                            Std. Deviation 
0.479 
0.065 
0.507 
0.065 
0.020 
Cg233330212     Mean 
                            Std. Deviation 
0.460 
0.047 
0.480 
0.046 
0.033 
Cg06991510      Mean 
                            Std. Deviation 
0.0233 
0.0111 
0.0192 
0.0091 
0.056 
Cg22830701       Mean 
                            Std. Deviation 
0.189 
0.142 
0.143 
0.107 
0.086 
Cg00298481       Mean 
                            Std. Deviation 
0.0774 
0.0110 
0.0735 
0.0099 
0.080 
Cg25328597       Mean 
                            Std. Deviation 
0.0520 
0.0099 
0.0475 
0.0098 
0.020 
Cg15688670       Mean 
                            Std. Deviation 
0.0369 
0.0119 
0.0419 
0.0158 
0.090 
Cg16257091       Mean 
                            Std. Deviation 
0.213 
0.063 
0.193 
0.404 
0.070 
Cg17413943      Mean 
                            Std. Deviation 
0.156 
0.034 
0.169 
0.039 
0.083 
Cg21010859       Mean 
                            Std. Deviation 
0.0376 
0.0177 
0.0309 
0.0163 
0.060 
Cg18867480       Mean 
                            Std. Deviation 
0.135 
0.022 
0.127 
0.017 
0.045 
Table 4: Average methylation of gene regions in the BDNF gene. Reported numbers are 
averaged β-values while P values are reported after Bonferroni correction. 
BDNF Gene Location Methylation AUD 
Cases (Average β-
value) 
Methylation 
Controls (Average 
β-value) 
P-Value 
Promoter        Mean 
                       Std. Deviation 
0.0761 
0.0184 
0.0718 
0.0110 
0.187 
5’UTR            Mean 
                       Std. Deviation 
0.190 
0.005 
0.190 
0.005 
0.957 
First Exon      Mean 
                       Std. Deviation 
0.334 
0.009 
0.332 
0.007 
0.180 
Gene Body     Mean 
                       Std. Deviation 
0.312 
0.006 
0.314 
0.006 
0.093 
3’UTR            Mean 
                        Std. Deviation 
0.823 
0.042 
0.826 
0.035 
0.688 
FIGURES 
 
Figure 1:  Average methylation of promoter region of the BDNF gene in AUD cases vs controls 
(p=0.187). 
 
Figure 2:  Average methylation of 5’UTR region of the BDNF gene in AUD cases vs controls 
(p=0.957). 
 Figure 3:  Average methylation of First Exon of the BDNF gene in AUD cases vs controls 
(p=0.180). 
 
Figure 4:  Average methylation of gene body of the BDNF gene in AUD cases vs controls 
(p=0.093) 
 Figure 5:  Average methylation of 3’UTR of the BDNF gene in AUD cases vs controls 
(p=0.688). 
 
 
 
